(Circulation. 1995;92:1876-1882.)
© 1995 American Heart Association, Inc.
Articles |
In Vivo Spin Trapping of Glyceryl Trinitrate–Derived Nitric Oxide in Rabbit Blood Vessels and Organs
From the Center of Physiology, Johann-Wolfgang-Goethe University Clinic, Frankfurt (A.M., P.M., R.B.); the Department of Applied Physiology, University of Freiburg (E.B.); and the Institute of Pharmaceutical Chemistry, Christian-Albrechts-University, Kiel (F.J., B.C.), Germany.
Correspondence to Alexander Mülsch, PhD, Zentrum der Physiologie, Klinikum der Universität Frankfurt, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany.
 |
Abstract |
|---|
 Top Abstract IntroductionMethods Results Discussion References |
|---|
Background The objectives of this study were (1) to assess glyceryl trinitrate (GTN)–derived nitric oxide (NO) formation in vascular tissues and organs of anesthetized rabbits in vivo, (2) to establish a correlation between tissue NO levels and a biological response, and (3) to verify biotransformation of GTN to NO by cytochrome P-450.
Methods and Results NO was trapped in tissues in vivo as a stable paramagnetic mononitrosyl-iron-diethyldithiocarbamate complex [NOFe(DETC)2]. After removal of the tissues, NO was determined by cryogenic electron spin resonance spectroscopy. NO formation in vitro was assessed by spin trapping and by activation of soluble guanylyl cyclase. The GTN-elicited decrease in coronary perfusion pressure was monitored in isolated, constant-flow perfused rabbit hearts. NO was not detected in control tissues. In GTN-treated rabbits, NO formation was higher in organs than in vascular tissues and higher in venous than in arterial vessels. In isolated hearts, ventricular NO levels and decreases in coronary perfusion pressure achieved by GTN were closely correlated. Purified cytochrome P-450 catalyzed NO formation from GTN in a P-450–NADPH reductase– and NADPH–dependent fashion.
Conclusions Since GTN-derived NO formation in myocardial tissue correlates to the GTN-elicited vasodilator response, we conclude that GTN-derived NO detected in vivo correlates with the systemic effects of GTN. Therefore, the higher rate of NO formation detected in veins compared with arteries explains the preferential venodilator activity of GTN. High NO formation in cytochrome P-450–rich organs in vivo and efficient NO formation from GTN by cytochrome P-450 in vitro highlights the importance of this pathway for NO formation from GTN in the intact organism.
Key Words: arteries • spectroscopy • glyceryl trinitrate • nitric oxide • veins
|
Introduction |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
GTN elicits vasodilatation by generating NO from one of its nitroester groups, which activates soluble GC and the cGMP-dependent effector cascade that finally leads to relaxation of the vascular smooth muscle.1 2 3 4 5 At the cellular level, indirect evidence shows that cultured vascular endothelial cells,6 smooth muscle cells,7 kidney epithelial cells,8 and lung fibroblasts9 generate NO from GTN, suggesting a widespread expression of the GTN-NO pathway in vascular and nonvascular tissues. Although this mechanism of GTN action is now generally accepted, a correlation between GTN-elicited tissue NO levels and a biological response has never been established. So far, NO formation in blood and organs of living mice could be detected only after application of toxic doses (25 and 40 mg/kg) of GTN.10 11 Recently, nitrosylhemoglobin was detected in blood of patients treated with therapeutic doses of GTN,12 but other tissues were not assessed. Therefore, the efficiency of vascular and nonvascular tissues in generating NO from GTN in vivo is still unknown. For instance, venous capacitance vessels are approximately one order of magnitude more sensitive to GTN than most arterial conductance and resistance vessels.13 In fact, the beneficial effect of GTN in angina pectoris therapy relies on this discrepant vasodilator responsiveness: predominant venodilatation results in preload reduction13 14 and economizes heart work. On the other hand, the relative insensitivity of the myocardial resistance bed (small arteries and arterioles) is also beneficial, since it prevents a coronary "steal" effect.15 Since these differences are not evident with authentic NO and S-nitrosothiols,15 they are unlikely to originate at the level of activation of soluble GC and/or the cGMP effector cascade but may reflect a different efficiency of vascular tissues to generate NO from GTN.15 16 17
The present study was performed (1) to assess NO formation from GTN in vascular tissues and several organs of rabbits in vivo, (2) to reveal a relation between GTN-elicited tissue NO levels and a biological response of this tissue, and (3) to assess whether tissue-specific differences in GTN-derived NO formation exist. Furthermore, since the molecular mechanism of NO release from GTN in vivo is still elusive, we analyzed the catalytic activity of cytochrome P-450 in generating NO from GTN.
|
Methods |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
Isolated Rabbit Heart
Beating hearts were removed from anesthetized (60 mg/kg sodium pentobarbitone) and heparinized (3000 U IV) New Zealand White rabbits (2.5 to 4 kg; SAVO) of either sex according to the Langendorff technique.18 The hearts were perfused through the aortic stump with modified Krebs-Henseleit solution (pH 7.4, 37°C, continuously gassed with 95% O2/5% CO2) containing (in mmol/L) NaCl 118.0, NaHCO3 24.0, glucose 5.0, CaCl2 2.5, KCl 4.0, KH2PO4 1.2, MgSO4 1.0, and pyruvate 2.0, with perfusion rate adjusted to generate a CPP of
70 mm Hg (30
to 40 mL/min). CPP was monitored with a pressure transducer (Gould
P2310) connected to the side arm of the aortic perfusion cannula.
Isovolumetric left ventricular pressure was measured with a
fluid-filled latex balloon connected to a second pressure
transducer (Gould CP-01). The heart rate was derived from the left
ventricular pressure signal. After an equilibration period, the NO synthase inhibitor NG-nitro-L-arginine (30 µmol/L) was continuously infused to raise resting CPP, thereby increasing the absolute value (in mm Hg) of the CPP decrease to a maximally effective dose of GTN. When CPP had stabilized (after about 15 minutes), GTN dissolved in 50 µL Krebs-Henseleit solution was injected into the perfusion line proximal to the heart as a bolus (0.1, 0.25, and 1 µmol) to elicit a transient decrease in CPP. After CPP returned to baseline, FeSO4 (0.3 µmol/L) dissolved in Krebs-Henseleit solution was infused for 15 minutes. This procedure lowered the detection limit of NO, since exogenous iron reduced formation of the Cu(DETC)2 complex, which interfered with ESR determination of NO (see below). Five minutes after cessation of FeSO4 infusion, DETC (50 µmol/L) was continuously infused. After 10 minutes, a second bolus of GTN was applied during continuous infusion of NG-nitro-L-arginine and DETC, and the perfusion was stopped 5 minutes later. Then the hearts were quickly disconnected from the perfusion line, and the ventricle was cut into small pieces and frozen in liquid nitrogen for ESR recording. CPP changes were evaluated for peak responses and for area under the curve of decrease in CPP versus time.
Animal Experiments
The following protocol was approved by the
local authorities
according to German regulations on experimental animal research. New
Zealand White rabbits were anesthetized (Nembutal 20 mg/kg IV,
left ear), and GTN (0.5 mg/kg) was infused (30 mL/h IV, right ear) for
20 minutes, concomitantly with DETC (200 mg/kg). DETC infusions were
well tolerated by the animals without signs of excitation. Immediately
after cessation of the infusion, the animals were killed by an overdose
of Nembutal (50 mg/kg IV). The carotid artery was opened, and a sample
of blood was quickly collected for later ESR analysis.
Subsequently, tissues of interest, eg, abdominal and thoracic aorta,
femoral arteries, vena cava, mesenteric bed, heart, lung, liver,
kidney, spleen, and skeletal muscle (quadriceps), were quickly excised
(within 10 minutes) and frozen for ESR analysis in liquid
nitrogen, as described previously.19
Background of NO Spin Trapping In Vivo
DETC distributes
freely within the organism.19 It
chelates intracellular free iron ions to form a water-insoluble
Fe(DETC)2 complex that is deposited in hydrophobic cell
compartments.11 19 The Fe(DETC)2 complex
avidly and selectively scavenges NO, generating a paramagnetic
mononitrosyl-iron complex,
NOFe(DETC)2.11 19 This complex exhibits a
characteristic anisotropic ESR signal, which is characterized by
g-factors g
=2.035, g||=2.02
(=perpendicular; ||=parallel), with a
triplet hfs at
g and a splitting constant of 1.3
mT11 19
(Fig 1
, top).
|
Calculation of Tissue NO Concentrations
The concentration of
NO trapped (nmol/g tissue) was calculated
from the amplitude of the third high-field hfs line, which is not
masked by other ESR signals, such as that of the copper-DETC complex
(see "Results"). The concentration of the NOFe(DETC)2
complex was calculated by comparing its ESR signal amplitude with that
of the g=2.039 ESR feature of the
dinitrosyl-iron-di-L-cysteine complex
recorded at known concentration.19 The ratio of both
amplitudes at equal concentrations is 1:1.3 (mononitrosyl versus
dinitrosyl complex), as calculated previously by double integration.
For samples shorter than 20 mm (blood vessels), a correction factor was
applied, derived from a calibration curve of the ESR signal intensity
plotted versus the sample length. This relation was obtained by
measuring the signal intensity of cylindrical (4.5-mm-diameter)
standards (dinitrosyl-iron-di-L-cysteine complex;
0.1 mmol/L) of different lengths (2 to 20 mm).
Recording of ESR Spectra and Estimation of the Tissue
Concentration of Traps
The ESR spectra were recorded at 77 K on a
Brucker 300E
spectrometer at a frequency of 9.33 GHz, modulation frequency 100 kHz,
modulation 0.5 or 1 mT, microwave power 20 mW, and time constant 0.05
seconds. After the first ESR analysis, the NO trapping capacity
(concentration of iron-DETC complex) of selected tissues was assessed
as described previously.19 In short, the tissues were
thawed, exposed to gaseous NO (400 mm Hg pressure), refrozen, and
analyzed again by ESR spectroscopy. The concentration of
mononitrosyl-iron complex detected under these conditions is
equivalent to the concentration of traps. This value also provides an
estimate of the so-called labile nonheme iron pool, which interacts
with DETC.19
Spin Trapping of NO in Aqueous Phase
PDTC was used to detect
release of NO from GTN in aqueous
solution in vitro, since the iron- and mononitrosyl-iron complexes
of PDTC are soluble in water, in contrast to the DETC complexes.
The ESR signals of the DETC and the PDTC mononitrosyl-iron complex
are identical and exhibit the same magnetic saturation behavior
(unpublished results). Therefore, the concentration of NO trapped by
Fe(PDTC)2 could be calculated from the ESR signal amplitude
as described for the DETC complex.
The stock trapping solution was
prepared by mixing 1 part of aqueous
FeSO4 (1 mol/L) solution and 19 parts of PDTC (0.2 mol/L)
in DMSO. NO donors were incubated at 37°C in HEPES buffer (15 mmol/L,
pH 7.4, 0.5 mL) containing DTT (10 mmol/L), superoxide dismutase (1
µmol/L), and 1:100 diluted stock trapping solution (final
concentration, 2 mmol/L PDTC and 0.5 mmol/L Fe2+). Under
these conditions, trapping of NO from various sources (NO gas, sodium
nitroprusside, SIN-1, S-nitroso-L-cysteine)
was optimal with respect to recovery of NO (approaching 100%),
linearity (from 0.1 to 100 µmol/L NO), sensitivity (100 nmol/L NO),
specificity (specific for NO and NO-releasing compounds), and stability
of the NOFe(PDTC)2 complex (stable for more than 2 hours)
(data not shown). It should be noted that oxygen levels were strongly
reduced in these incubates owing to oxygen consumption by DTT (measured
by an oxygen-sensitive electrode). For assessment of cytochrome
P-450–catalyzed NO formation, the trapping solution was incubated with
GTN (30 µmol/L), NADPH (300 µmol/L),
L-
-dilauroyl-phosphatidylcholine (10
µmol/L), pure cytochrome P-450 (400 pmol), and cytochrome
P-450–NADPH reductase (400 pmol) for either 10 or 60 minutes at
37°C. Subsequently, the samples were frozen in liquid nitrogen and
kept at -70°C until analyzed by ESR spectroscopy.
Detection of NO by GC
The activity of soluble GC purified to
apparent homogeneity from
bovine lung was assessed by formation of [32P]cGMP from
[32P]GTP, as described previously.7 GC
(4
µg protein/mL) was incubated at 37°C for 3, 10, or 30 minutes, as
indicated in the legend to Fig 4, in a triethanolamine
hydrochloride–buffered solution (30 mmol/L, pH 7.4) containing 200
µmol/L [32P]GTP (0.2 µCi), 100 µmol/L
unlabeled
cGMP, 4 mmol/L MgCl2, 100 nmol/L erythrocyte
superoxide dismutase, 0.1 mg/mL bovine 
-globulin, 10 mmol/L
creatine phosphate, 120 µg/mL creatine phosphokinase (1 U/mL), and
200 µmol/L NADPH, purified rabbit liver cytochrome P-450, and
cytochrome P-450–NADPH reductase, as indicated. Incubations were
stopped by coprecipitation of nucleotides with zinc
carbonate. After centrifugation,
[32P]cGMP was isolated from the supernatant by
chromatography on acid alumina and was determined by
liquid scintillation counting in a ß-counter (Packard). The specific
activity of GC (nanomoles of cGMP formed per milligram GC per
minute incubation time) was calculated as described.7 In
the absence of NO, soluble GC exhibited a basal activity, which was
subtracted from the values shown in Fig 4.
|
, -NADPH; 
, +NADPH). B, Time course of GC activation by
P-450 (200 nmol/L) and GTN (100 µmol/L). Incubations proceeded for 1,
3, 10, and 30 minutes, either in the absence (
), and in the presence of P-450 and NADPH
(200 µmol/L;
Materials
Cytochrome P-450 and cytochrome P-450–NADPH
reductase were
purified to apparent homogeneity from rabbit liver.20
Nembutal was from Sanofi Winthrop. PDTC was a generous gift of Dr N.
Frank, German Cancer Research Center, Heidelberg. GTN was provided as a
trituration in lactose (10% GTN) by Pohl-Boskamp. All other
biochemicals were obtained in the highest purity available from
Sigma.
Statistics
Data are presented as mean±SEM. The
significance of
differences between NO concentrations achieved in venous and
arterial tissues was assessed by one-way ANOVA,
followed by the Bonferroni t test. A value of
P<.05 was considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
NO Formation In Vivo
Frozen tissues obtained from DETC-treated control animals exhibited ESR spectra that were dominated by the resonance of the copper-DETC complex,11 19 as shown for a control heart in Fig 1
. The intensity of this ESR signal varied
considerably between different tissue types, representing
differences in the content of the Cu(DETC)2 complex (data
not shown). The ESR signal of NOFe(DETC)2 was absent from
control tissues, indicating that endogenous,
L-arginine–derived NO formation4 was
below the detection limit of our ESR installation. In contrast, tissues
removed from GTN-infused rabbits exhibited ESR features of the
NOFe(DETC)2 complex. In blood vessels, spleen, and heart,
only the third hfs line of this ESR signal was clearly visible (labeled
3 in Fig 1), while the first and second hfs lines,
clearly
discernible in the ESR spectrum of the pure NOFe(DETC)2
complex (labeled 1 and 2 in the top recording, Fig 1),
were masked by the resonance of the Cu(DETC)2 complex. With
higher NO levels, such as observed in the lung, liver, and kidney, the
first hfs line of the NOFe(DETC)2 complex also became
visible (labeled 1 in Fig 1). Evaluation of all tissues
(from eight
rabbits) revealed significant differences in NO formation achieved by
GTN treatment (Fig 2). It was significantly higher in
the vena cava and the mesenteric bed than in the femoral artery and
thoracic and abdominal aorta (P<.05). The concentration of
trapped NO was considerably higher in liver, lung, and kidney, up to
1.65 nmol/g. GTN-derived NO was not detectable in whole blood or in
skeletal muscle (quadriceps) (Fig 2).
|
After the first
ESR analysis for GTN-derived NO, a second
ESR analysis was performed for estimation of the concentration
of NO traps [Fe(DETC)2 complexes]. This concentration was
significantly lower in blood vessels than in organs (Table 1,
left
column; P<.05). However, in all tissues,
only a small fraction (0.5% to 4.5%) of the total amount of traps
available was required for binding of GTN-derived NO (Table 1).
|
Correlation Between Myocardial NO Formation and Relaxation of
Coronary Resistance Vessels
In isolated rabbit hearts (n=6),
continuous infusion of
NG-nitro-L-arginine (30
µmol/L) increased resting CPP from 73±6 to 111±8 mm Hg. GTN
applied as a bolus (0.1, 0.25, and 1 µmol) elicited a
dose-dependent transient decrease in peak CPP (Fig 3),
maximally 50±1% at 1 µmol. After the CPP
response, FeSO4 (0.3 µmol/L for 15 minutes) was infused
to provide additional iron required for formation of NO traps
[Fe(DETC)2 complex]. FeSO4 slightly increased
CPP (by 8.5±6%). Subsequent infusion of DETC (50 µmol/L) did not
alter CPP (0.5±1.3% change). After 10 minutes of DETC infusion, the
decrease in CPP to a second GTN bolus was significantly attenuated
compared with the decrease elicited by GTN before DETC infusion: peak
responses to all doses of GTN were reduced by 5±1%, and the area
under the curve (CPP decrease integrated from 0 to 5 minutes of GTN
application) was reduced by 74±5%, 42±6%, and 16±4% at
0.1, 0.25,
and 1 µmol GTN, respectively. As shown in Fig 3, tissue NO
levels
achieved during this second GTN exposure were positively correlated to
the dose of GTN applied and to the GTN-elicited peak decrease in CPP.
Interestingly, the NO level generated by 1 µmol of GTN in isolated
hearts after 5 minutes (0.04 nmol/g) was about 10-fold lower than that
detected in the same tissue in vivo after infusion of 10 µmol (2 mg
per animal) of GTN during 20 minutes (0.45 nmol/g; Fig 2). This
indicates a rather similar dose-effect relation in rabbit hearts in
vitro and in vivo.
|
Cytochrome P-450–Catalyzed NO Formation From GTN
The
high in vivo NO formation in the cytochrome P-450–rich organs
liver, lung, and kidney prompted us to assess the ability of cytochrome
P-450, purified from rabbit liver, to generate NO from GTN in vitro.
Two different detection techniques were used that operate at reduced
and at ambient oxygen concentrations: (1) NO spin trapping in aqueous
solution by Fe(PDTC)2, which unavoidably proceeds
under nearly anaerobic conditions due to oxygen consumption
by DTT (10 mmol/L; see "Methods"), and (2) activation of soluble
GC, which is assessed at ambient oxygen levels in aqueous solution.
Both techniques yielded consistent results.
ESR spectroscopy revealed
that cytochrome P-450 transiently enhanced NO
formation from GTN (Table 2), 26 times the control
(P-450–free) value at 10 minutes and 4.1 times control at 60 minutes
of incubation, in the presence of NADPH and cytochrome P-450–NADPH
reductase (Table 2, line 1). Without the reductase, NO
formation by
cytochrome P-450 was attenuated but still significantly higher than
controls (compare lines 2 and 4, Table 2). The reductase itself
was not
capable of generating NO from GTN (Table 2, line 3). In
contrast to the
transient nature of P-450–catalyzed NO formation, the low spontaneous
NO formation (Table 2, line 4) resulting from reductive
hydrolysis of
GTN by DTT proceeded at a constant rate for up to 1 hour. The
involvement of nitrite as a source of P-450–dependent NO formation was
excluded, since NO formation by sodium nitrite (30 µmol/L) equaled
spontaneous NO formation by GTN (30 µmol/L) (Table 2, line
5).
|
Cytochrome P-450 also catalyzed NO formation from GTN in the
presence
of oxygen, as detected by activation of soluble GC (Fig 4). The
enhancement of basal GC activity (45±5
nmol · mg-1 · min-1) increased
with
the concentration of GTN (Fig 4A) and cytochrome P-450 (Fig
4C),
resulting in fourfold to sixfold higher GC activity at maximally
effective concentrations of GTN and cytochrome P-450. The reductase was
omitted in these experiments because it directly inhibited soluble GC
activity in an NADPH-dependent fashion (data not shown). Cytochrome
P-450–catalyzed activation of soluble GC by GTN was transient, peaking
at 3 to 10 minutes of incubation (Fig 4B), thus confirming the
previous
findings obtained under anaerobic conditions. In the
absence of cytochrome P-450, basal GC activity was slightly enhanced
(0.75±0.15-fold) by higher concentrations of GTN (100 and 300
µmol/L) (Fig 4) due to a low level of NO generated by
nonenzymatic
release of nitrite (assessed by the Griess
reaction21 ).
|
Discussion |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
GTN, like other organic nitrates, is believed to act as a vasodilator by releasing NO from one of its nitroester groups.1 2 3 4 5 However, this hypothesis still requires confirmation, since (1) no firm correlation has been established between tissue levels of NO and a pharmacological response to GTN in vascular and nonvascular tissues; (2) direct evidence for NO formation from GTN in vascular tissues in vivo is lacking; (3) the pharmacodynamics (pattern of NO formation in different tissues of the intact organism) of GTN are unknown, thus leaving the large variation in the sensitivity of different vascular beds to GTN unexplained; and (4) the molecular mechanism of biotransformation of GTN to NO in vivo is still unresolved. In an attempt to substantiate the "GTN-NO hypothesis," we now used an NO spin-trapping technique to monitor NO formation in isolated rabbit hearts and in different tissues of anesthetized rabbits exposed to GTN. We observed that (1) the GTN-elicited dilation of the coronary resistance bed (decrease in CPP) of isolated rabbit hearts was positively correlated to ventricular levels of NO; (2) GTN generated different levels of NO in several vascular tissues and organs; (3) NO levels were higher in the vena cava and the mesenteric bed compared with the aorta and femoral artery; and (4) purified cytochrome P-450 of rabbit liver catalyzed NO formation from GTN in vitro under aerobic and under unaerobic conditions.
Taken together, these findings support the hypothesis that GTN elicits
vascular relaxation in vivo by releasing NO. Given that the strong
correlation between tissue NO levels and vasodilation in the
coronary resistance bed (Fig 2) also holds true for other
vascular tissues, the finding that higher levels of NO were detected in
the vena cava and the mesenteric bed than in the aorta and femoral
artery (Fig 2) provides an explanation for the preferential
venodilator
activity of GTN.13 14 15 Several factors
are potentially able
to influence NO levels in a given tissue: tissue-specific
bioavailability of GTN within the organism, relative rates of
"inactivation" (nitrite formation by vascular GSH
transferases22 ) and "activation" (NO formation) of
GTN, and inactivation of NO (by superoxide anion radicals and
hemoproteins). Limited bioavailability of GTN may be responsible for
the low NO levels observed in the aorta, since extraction of infused
GTN across this vessel is extremely low.23 24 In
contrast,
uptake of GTN by the vena cava, the mesenteric bed, and the femoral
artery is similarly high.23 24 Therefore,
bioavailability
differences do not exist between these vascular tissues. Furthermore,
according to in vitro studies with isolated vessels, overall
metabolism of GTN to nitrite and glyceryldinitrates (via
GSH transferase and via NO formation, respectively) would appear to be
similar in the vena cava and the aorta.24 Since inhibition
of nitrite formation from GTN by GSH transferase inhibitors
does not affect the vasodilator activity of GTN,22 it can
be assumed that GTN-inactivating pathways (GSH transferases) do not
significantly affect the formation of NO from GTN in vascular tissues.
Finally, recent evidence indicates that inactivation of NO by reaction
with superoxide anion radicals4 25 must be considered
as a
general principle controlling vascular NO levels. For example,
vasodilator responses to GTN are attenuated in atherosclerotic compared
with healthy blood vessels,26 because the former generated
higher amounts of superoxide anion radical than the nonatherosclerotic
controls. This impaired vasodilator responsiveness to GTN was abolished
by addition of superoxide dismutase. However, if superoxide levels in
nonatherosclerotic venous and arterial tissues were
different (which is unknown) and of critical importance for control of
tissue NO levels, all vasodilators acting by release of NO should
exhibit a similar vessel type specificity. This is clearly not the
case. Sodium nitroprusside, for instance, in some vascular beds
exhibits a vasodilator profile quite opposite to GTN.15
Furthermore, we analyzed vascular NO formation by the
spontaneously NO-releasing nitrovasodilator SIN-1 (0.5
mg · kg-1 · 20 min-1 IV)
infused to
anesthetized rabbits. SIN-1 elicited significantly higher NO
levels in arterial tissues (aorta, 0.25±0.05 nmol/g;
femoral artery, 0.45±0.05 nmol/g; n=4) than an identical dose of
GTN
(Fig 2). In contrast, SIN-1 and GTN generated similar NO levels
in the
vena cava (0.45±0.05 nmol/g). This finding, too, rules out that
different superoxide levels or different rates of inactivation of NO
account for discrepant NO levels elicited by GTN in vascular tissues.
We conclude that the rate of biotransformation of GTN to NO is the
limiting factor controlling NO levels in vascular tissues.
We can exclude any influence of the trapping capacity of a given tissue
on the amount of NO detected. For instance, traps
[Fe(DETC)2] were approximately equally distributed in
vascular tissues, ranging from 6 (abdominal aorta) to 13 (mesenteric
bed) nmol/g, but the fractional occupation of traps by GTN-derived NO
varied from 0.5% (thoracic aorta) to 4.5% (vena cava) (Table
1).
Similarly, the content of traps in organs was unrelated to the amount
of NO detected (compare spleen and kidney, for instance). Efficient
trapping of NO by iron-DETC is indicated by previous findings showing
that DETC significantly attenuated the vasodilator response of isolated
blood vessels27 and the decrease in systemic
arterial blood pressure in response to NO
donors.28
A surprising finding was the high rate of NO formation in several
organs, equal to (heart, spleen) or even exceeding (lung, liver, and
kidney) venous NO formation. Considering the reportedly low vasodilator
sensitivity of the coronary and hepatic resistance bed to
GTN15 29 and the low content of vascular tissue in
the
heart, liver, and kidney, nonvascular cells are likely to account for
NO formation from GTN in these organs. According to in vitro studies
with isolated deoxymyoglobin (Reference 30 and A. Mülsch,
unpublished results), at least in the heart this reaction could be
catalyzed by deoxymyoglobin present in
cardiomyocytes.31 Furthermore, since liver,
lung, and kidney are rich in cytochrome P-450, and we observed
efficient NO formation from GTN by purified cytochrome P-450 from
rabbit liver (Fig 4; Table 2), it is highly
probable that cytochrome
P-450 is a major pathway of NO formation from GTN in these
organs.32 In support of this conclusion,
anaerobic denitration of GTN and formation of nitrite by
cytochrome P-450 in rat liver microsomes accounts for 30% to 40% of
the total denitration in rat liver.33 Therefore, this
pathway may decisively contribute to the GTN-elicited vasodilatation of
resistance beds in organs.15 29
Furthermore, since cytochrome P-450 has been proposed as a likely
candidate to catalyze formation of NO by GTN in vascular
tissues,5 9 34 35 as well as
an as yet unidentified
tetrameric 200-kD protein,36 this topic also remains a
matter of debate.37 Cytochrome P-450–like activity and
immunoreactivity are present in low amounts in the vascular wall,
the distribution between endothelium and smooth muscle
layer depending on the vessel type and species.38 39
The
present study demonstrates that cytochrome P-450 catalyzes NO
formation both in the absence (Table 2) and presence (Fig
4) of oxygen.
Although purified cytochrome P-450–NADPH reductase enhanced this NO
formation, cytochrome P-450 was active per se and required NADPH only
as a cofactor. Formation of NO from the nitroester moiety of GTN
implies a reduction of the nitrogen atom by three electrons. This could
be accomplished by direct electron transfer from the cytochrome
P-450–heme. Several other reductive reactions catalyzed by cytochrome
P-450 have been described.40 41 Furthermore, a
direct,
reductase-independent substrate reduction by cytochrome P-450, as
observed in the present study (Fig 4), is not without
precedent.
The fungal cytochrome P-450 55A1 has been shown to catalyze the
reduction of NO in an NADH-dependent fashion, without requiring
additional proteinaceous components or redox-active
mediators,42 and another fungal cytochrome P-450 was able
to generate NO from GTN.43
For the first time, we provide direct evidence that GTN generates NO in vascular tissues in vivo and that NO levels and vasodilator responses elicited by GTN in isolated perfused rabbit hearts are closely correlated. Furthermore, we demonstrate that venous tissue generates higher levels of NO from GTN than arterial tissue. This finding accounts for the prevailing venodilator activity of GTN. Surprisingly, NO formation was equal or even higher not only in the liver but also in several other organs previously not considered to express the GTN-NO pathway. Since cytochrome P-450 is abundant in these organs and we observed efficient catalysis of NO formation from GTN by reconstituted rabbit liver cytochrome P-450–NADPH reductase, this pathway probably accounts for NO formation by GTN in these organs.
|
Selected Abbreviations and Acronyms |
|---|
|
)/(ß · HR), where h is the
Planck constant,
|
Acknowledgments |
|---|
This study was supported by the Deutsche Forschungsgemeinschaft (Bu 436/4-3, BA 408/13-2, and Mü 900/4-1) and by Pohl-Boskamp, Hohenlockstedt, Germany. We thank Dr Norbert Frank, German Cancer Research Center, Heidelberg, for synthesis of PDTC and Dr Ingrid Fleming for helpful suggestions.
Received January 10, 1995; revision received February 20, 1995; accepted April 17, 1995.
|
References |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
1. Waldman SA, Murad F. Cyclic GMP synthesis and function. Pharmacol Rev. 1987;39:163-196. [Medline] [Order article via Infotrieve]
2. Walter U. Physiological role of cGMP and cGMP-dependent protein kinase in the cardiovascular system. Rev Physiol Biochem Pharmacol. 1989;113:41-88. [Medline] [Order article via Infotrieve]
3. Blayney LM, Gapper PW, Newby AC. Inhibition of a receptor-operated calcium channel in pig aortic microsomes by a cyclic GMP-dependent protein kinase. Biochem J. 1991;273:803-806.
4. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-142. [Medline] [Order article via Infotrieve]
5. Bennett BM, McDonald BJ, Nigam R, Simon WC. Biotransformation of organic nitrates and vascular smooth muscle cell function. Trends Pharmacol Sci. 1994;15:245-249. [Medline] [Order article via Infotrieve]
6. Feelisch M, Kelm M. Biotransformation of organic nitrates to nitric oxide by vascular smooth muscle and endothelial cells. Biochem Biophys Res Commun. 1991;180:286-293. [Medline] [Order article via Infotrieve]
7. Mülsch A, Busse R, Winter I, Bassenge E. Endothelium- and sydnonimine-induced responses of native and cultured aortic smooth muscle cells are not impaired by nitroglycerin tolerance. Naunyn Schmiedebergs Arch Pharmacol. 1989;339:568-574. [Medline] [Order article via Infotrieve]
8. Schröder H, Schrör K. Inhibitors of cytochrome P-450 reduce cyclic GMP stimulation by glyceryltrinitrate in LLC-PK2 kidney epithelial cells. Naunyn Schmiedebergs Arch Pharmacol. 1990;342:616-618. [Medline] [Order article via Infotrieve]
9.
Schröder H. Cytochrome P-450 mediates
bioactivation of organic nitrates. J Pharmacol
Exp Ther. 1992;262:298-302.
10. Kuropteva ZV, Pastushenko ON. Change in paramagnetic blood and liver complexes in animals under the influence of nitroglycerin. Dokl Akad Nauk SSSR. 1985;281:189-192. [Medline] [Order article via Infotrieve]
11. Vanin AF, Mordvintcev PI, Kleshchev AL. Appearance of nitrogen oxide in animal tissues in vivo. Stud Biophys. 1984;102:135-143.
12. Cantilena LR, Smith RP, Frasur S, Kruszyna H, Kruszyna R, Wilcox DE. Nitric oxide hemoglobin in patients receiving nitroglycerin as detected by electron paramagnetic resonance spectroscopy. J Lab Clin Med. 1992;120:902-907. [Medline] [Order article via Infotrieve]
13.
Ferrer MI, Bradley SE, Wheeler HO, Enson Y, Preiseg R,
Brickner PW, Conroy RJ, Harvey RM. Some effects of
nitroglycerin upon the splanchnic, pulmonary,
and systemic circulations. Circulation. 1966;33:357-373.
14. Loos D, Schneider R, Schörner W. Changes in regional blood volume caused by nitroglycerin. Z Kardiol. 1983;72(S3):29-32.
15.
Kurz MA, Lamping KG, Bates JN, Eastham CL, Marcus ML,
Harrison DG. Mechanisms responsible for the
heterogeneous coronary microvascular response to
nitroglycerin. Circ Res. 1991;68:847-855.
16.
Brien JF, McLaughlin BE, Breedon TH, Bennett BM,
Nakatsu K, Marks GS. Biotransformation of glyceryl trinitrate
occurs concurrently with relaxation of rabbit aorta.
J Pharmacol Exp Ther. 1986;237:608-614.
17. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest. 1986;78:1-5.
18. Lamontagne D, König A, Bassenge E, Busse R. Prostacyclin and nitric oxide contribute to the vasodilator action of acetylcholine and bradykinin in the intact coronary bed. J Cardiovasc Pharmacol. 1992;20:652-657. [Medline] [Order article via Infotrieve]
19. Mülsch A, Mordvintcev P, Vanin A. Quantification of nitric oxide in biological samples by electron spin resonance spectroscopy. Neuroprotocols. 1992;1:165-173.
20. Clement B, Jung F, Pfundner H. N-Hydroxylation of benzamidine to benzamidoxime by reconstituted cytochrome P-450 oxidase system from rabbit liver: involvement of cytochrome P-450 IIC3. Mol Pharmacol. 1992;43:335-342. [Abstract]
21.
Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G.
Endothelium-derived relaxing factor produced
and released from artery and vein is nitric oxide. Proc
Natl Acad Sci U S A. 1987;84:9265-9269.
22. Kurz MA, Boyer TD, Whalen R, Peterson TE, Harrison G. Nitroglycerin metabolism in vascular tissue: role of glutathione S-transferases and relationship between NO · and NO2- formation. Biochem J. 1993;292:545-550.
23.
Cossum PA, Roberts MS, Yong AC, Kilpatrick D.
Distribution and metabolism of
nitroglycerin and its metabolites in vascular beds of
sheep. J Pharmacol Exp Ther. 1986;237:959-966.
24.
Fung H-L, Sutton SC, Kamiya A. Blood vessel
uptake and metabolism of organic nitrates in the
rat. J Pharmacol Exp Ther. 1984;228:334-341.
25. Saran M. Reaction of NO with O2-: implications for the action of endothelium-derived relaxing factor (EDRF). Free Radic Res Commun. 1990;10:221-226. [Medline] [Order article via Infotrieve]
26. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993;91:2546-2551.
27. Vedernikov YP, Mordvintcev PI, Malenkova IV, Vanin AF. Effect of diethyldithiocarbamate on the activity of nitric oxide-releasing vasodilators. Eur J Pharmacol. 1992;212:125-128. [Medline] [Order article via Infotrieve]
28. Kleshchev AL, Mordvintcev PI, Vanin AF. Role of nitric oxide and iron in hypotensive action of nitrosyl iron complexes with various anion ligands. Stud Biophys. 1985;105:93-102.
29. Shepherd AN, Hayes PC, Jacyna M, Morrison L, Bouchier IA. The influence of captopril, the nitrates and propranolol on apparent liver blood flow. Br J Clin Pharmacol. 1985;19:393-397. [Medline] [Order article via Infotrieve]
30.
Bennett BM, Kobus SM, Brien JF, Nakatsu K, Marks GS.
Requirement for reduced, unliganded hemoprotein for the
hemoglobin- and myoglobin-mediated biotransformation of glyceryl
trinitrate. J Pharmacol Exp Ther. 1986;237:629-635.
31. Grote J, Thews G. Respiratory gas transport in heart. In: Bicher HI, Bruley DF, eds. Oxygen Transport to Tissue: Instrumentation, Methods and Physiology. New York, NY: Plenum Press; 1973:525-542.
32. Servant D, Delaforge M, Ducrocq C, Mansuy D, Lenfant M. Nitric oxide formation during microsomal hepatic denitration of glyceryl trinitrate: involvement of cytochrome P-450. Biochem Biophys Res Commun. 1989;163:1210-1216. [Medline] [Order article via Infotrieve]
33. Delaforge M, Servant D, Wirsta P, Ducrocq C, Mansuy D, Lenfant M. Particular ability of cytochrome P-450 CYP3A to reduce glyceryl trinitrate in rat liver microsomes: subsequent formation of nitric oxide. Chem Biol Interact. 1993;86:103-107. [Medline] [Order article via Infotrieve]
34. McDonald BJ, Bennett BM. Biotransformation of glyceryl trinitrate by rat aortic cytochrome P-450. Biochem Pharmacol. 1993;45:268-270. [Medline] [Order article via Infotrieve]
35. Bennett BM, McDonald BJ, Nigam R, Long PG, Simon WC. Inhibition of nitrovasodilator- and acetylcholine-induced relaxation and cyclic GMP accumulation by the cytochrome P-450 substrate, 7-ethoxyresorufin. Can J Physiol Pharmacol. 1992;70:1297-1303. [Medline] [Order article via Infotrieve]
36. Seth P, Fung H-L. Biochemical characterization of a membrane-bound enzyme responsible for generating nitric oxide from nitroglycerin in vascular smooth muscle cells. Biochem Pharmacol. 1993;46:1481-1486. [Medline] [Order article via Infotrieve]
37.
Liu Z, Brien JF, Marks GS, McLaughlin BE, Nakatsu K.
Lack of evidence for the involvement of cytochrome P-450 or
other hemoproteins in metabolic activation of glyceryl
trinitrate in rabbit aorta. J Pharmacol Exp
Ther. 1993;264:1432-1439.
38.
Abraham NG, Pinto A, Mullane KM, Levere RD, Spokas E.
Presence of cytochrome P-450-dependent
monooxygenase in intimal cells of the hog
aorta. Hypertension. 1985;7:899-904.
39. Serabjit-Singh CJ, Bend JR, Philpot RM. Cytochrome P-450 monooxygenase system: localization in smooth muscle of rabbit aorta. Mol Pharmacol. 1985;28:72-79. [Abstract]
40.
Appel KE, Graf H. Metabolic nitrite
formation from N-nitrosamines: evidence for a cytochrome P-450
dependent reaction. Carcinogenesis. 1982;3:293-296.
41. Mansuy D. Reactive intermediates derived from cytochrome P-450 monooxygenases. In: Sund H, Ullrich V, eds. Biological Oxidations. Berlin, Germany: Springer-Verlag; 1983:240-246.
42.
Nakahara K, Tanimoto T, Hatano K, Usuda K, Shoun H.
Cytochrome P-450 55A1 (P-450dNIR) acts as a nitric oxide
reductase employing NADH as the direct electron donor.
J Biol Chem. 1993;268:8350-8355.
43. Servent D, Ducrocq C, Henry Y, Guissani A, Lenfant M. Nitroglycerin metabolism by Phanerochaete chrysosporium: evidence for nitric oxide and nitrite formation. Biochim Biophys Acta. 1991;1074:320-325.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  A. Tesse, G. Al-Massarani, R. Wangensteen, S. Reitenbach, M. C. Martinez, and R. Andriantsitohaina Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-{gamma} Agonist, Prevents Microparticle-Induced Vascular Hyporeactivity through the Regulation of Proinflammatory Proteins J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 539 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Gutterman Combating Nitrate Tolerance: A Novel Endogenous Mechanism Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1673 - 1676. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tesse, F. Meziani, E. David, N. Carusio, H. Kremer, F. Schneider, and R. Andriantsitohaina Microparticles from preeclamptic women induce vascular hyporeactivity in vessels from pregnant mice through an overproduction of NO Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H520 - H525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Meziani, A. Tesse, E. David, M. C. Martinez, R. Wangesteen, F. Schneider, and R. Andriantsitohaina Shed Membrane Particles from Preeclamptic Women Generate Vascular Wall Inflammation and Blunt Vascular Contractility Am. J. Pathol., October 1, 2006; 169(4): 1473 - 1483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tesse, M. C. Martinez, B. Hugel, K. Chalupsky, C. D. Muller, F. Meziani, D. Mitolo-Chieppa, J.-M. Freyssinet, and R. Andriantsitohaina Upregulation of Proinflammatory Proteins Through NF-{kappa}B Pathway by Shed Membrane Microparticles Results in Vascular Hyporeactivity Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2522 - 2527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Janero, N. S. Bryan, F. Saijo, V. Dhawan, D. J. Schwalb, M. C. Warren, and M. Feelisch Differential nitros(yl)ation of blood and tissue constituents during glyceryl trinitrate biotransformation in vivo PNAS, November 30, 2004; 101(48): 16958 - 16963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Muller, I. Konig, W. Meyer, and G. Kojda Inhibition of vascular oxidative stress in hypercholesterolemia by eccentric isosorbide mononitrate J. Am. Coll. Cardiol., August 4, 2004; 44(3): 624 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Gori and J. D. Parker Nitrate Tolerance: A Unifying Hypothesis Circulation, November 5, 2002; 106(19): 2510 - 2513. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tsuchiya, M. Yoshizumi, H. Houchi, and R. P. Mason Nitric Oxide-forming Reaction between the Iron-N-Methyl-D-glucamine Dithiocarbamate Complex and Nitrite J. Biol. Chem., January 21, 2000; 275(3): 1551 - 1556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Stoclet, M. C. Martinez, P. Ohlmann, S. Chasserot, C. Schott, A. L. Kleschyov, F. Schneider, and R. Andriantsitohaina Induction of Nitric Oxide Synthase and Dual Effects of Nitric Oxide and Cyclooxygenase Products in Regulation of Arterial Contraction in Human Septic Shock Circulation, July 13, 1999; 100(2): 107 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Rossig, B. Fichtlscherer, K. Breitschopf, J. Haendeler, A. M. Zeiher, A. Mulsch, and S. Dimmeler Nitric Oxide Inhibits Caspase-3 by S-Nitrosation in Vivo J. Biol. Chem., March 12, 1999; 274(11): 6823 - 6826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Jackson, A. Xu, J. A. Vita, and J. F. Keaney Jr Ascorbate Prevents the Interaction of Superoxide and Nitric Oxide Only at Very High Physiological Concentrations Circ. Res., November 2, 1998; 83(9): 916 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dikalov, B. Fink, M. Skatchkov, D. Stalleicken, and E. Bassenge Formation of Reactive Oxygen Species by Pentaerithrityltetranitrate and Glyceryl Trinitrate In Vitro and Development of Nitrate Tolerance J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 938 - 944. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Kojda, M. Patzner, A. Hacker, and E. Noack Nitric Oxide Inhibits Vascular Bioactivation of Glyceryl Trinitrate: A Novel Mechanism to Explain Preferential Venodilation of Organic Nitrates Mol. Pharmacol., March 1, 1998; 53(3): 547 - 554. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Dikalov, B. Fink, M. Skatchkov, O. Sommer, and E. Bassenge Formation of Reactive Oxygen Species in Various Vascular Cells During Glyceryltrinitrate Metabolism Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(1): 51 - 61. [Abstract] [PDF]
|
|
|
|
|
|
R. Yuan, M. Sumi, and L. Z. Benet J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1499 - 1505. [Abstract]
|
|
|
|
|
|
D. Giugliano, R. Marfella, L. Coppola, G. Verrazzo, R. Acampora, R. Giunta, F. Nappo, C. Lucarelli, and F. D'Onofrio Vascular Effects of Acute Hyperglycemia in Humans Are Reversed by L-Arginine : Evidence for Reduced Availability of Nitric Oxide During Hyperglycemia Circulation, April 1, 1997; 95(7): 1783 - 1790. [Abstract] [Full Text]
|
|
|
|
|
|
M. Skatchkov, L.L. Larina, A.A. Larin, N. Fink, and E. Bassenge Urinary Nitrotyrosine Content as a Marker of Peroxynitrite-induced Tolerance to Organic Nitrates Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(2): 85 - 96. [Abstract] [PDF]
|
|
|
|
|
|
J. B. Laursen, A. Mulsch, S. Boesgaard, P. Mordvintcev, S. Trautner, N. Gruhn, J. E. Nielsen-Kudsk, R. Busse, and J. Aldershvile In Vivo Nitrate Tolerance Is Not Associated With Reduced Bioconversion of Nitroglycerin to Nitric Oxide Circulation, November 1, 1996; 94(9): 2241 - 2247. [Abstract] [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||